United Health Care approves Pegasys for MPN
Effective July 2012, United Health Care now covers Peginterferon Alfa-2a (Pegasys) for treatment of myeloproliferative neoplasms Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (MF).
The change in UHC’s coverage policy resulted from a request by the MPN Research Foundation to amend its policy on Pegasys in light of the recent clinical trials showing the significant effectiveness in MPN patients. Click here for further details from UHC on their coverage of Pegasys. In January the Foundation was successful in requesting Cigna cover Pegasys for MPN patients.